



Supplementary Figure 3.


A.



B.



C.



**SFig. 3**

**A Effect of AZD0530 on SFK and EGFR phosphorylation.** LoVo and HCT116-p53wt cells were treated with increasing concentrations of SFK inhibitor AZD0530 for 24 hours and pSFK<sup>Y418</sup>, tSrc, pEGFR<sup>Y1068</sup> and tEGFR levels were determined by Western blotting. Equal loading was assessed by probing for β-tubulin.

**B Role of SFKs in rhTRAIL-induced apoptosis.** HCT116-p53wt and LoVo cells were treated with no drug (control), AZD0530 alone, rhTRAIL alone or AZD0530 in combination with rhTRAIL. Cells were exposed to AZD0530 for 24 hours followed by rhTRAIL for 24 hours, and the cell cycle status of the cells was monitored by flow cytometry after propidium iodide staining. Percentages of cells in sub-G0/G1 apoptotic phase are given.

**C Role of SFKs in rhTRAIL-induced TGF-α shedding.** LoVo and HCT116-p53wt cells were pre-incubated with 1 μM AZD0530 for 4 hours and then treated with rhTRAIL for 24 hours. Shedding of TGF-α into the medium was measured using a TGF-α ELISA kit.